Behind The Raise: Peripear

Why It Matters

Automating a proven warm‑compress intervention can slash costly birth injuries, improving outcomes for millions of women while delivering clear financial savings for hospitals.

Key Takeaways

• Warm perineal compression cuts severe tears by up to 50 %.
• 90 % of vaginal births experience perineal trauma worldwide.
• Peripear’s wearable priced $200+ saves $15k‑$70k per prevented tear.
• Singapore MOUs cover ~50 % of national births; US pilots underway.
• Pre‑seed round £800k (≈$1 M) 80% committed, backed by Zinc VC.

Pulse Analysis

Perineal trauma remains one of the most under‑addressed complications of vaginal delivery, affecting roughly nine out of ten women and costing health systems billions each year. Clinical research has long shown that warm compresses applied during crowning can halve the incidence of severe tears, yet the practice is rarely executed because caregivers’ hands are occupied. This gap creates a hidden burden of incontinence, chronic pain, and mental‑health sequelae that strain both patients and payers, with the NHS alone spending over £260 million (about $330 million) annually on treatment and litigation.

Peripear’s solution translates that evidence into a single‑use, hands‑free wearable that maintains therapeutic heat of 38 °C or higher while delivering controlled moisture. A feasibility study at Hadassah Hospital demonstrated strong clinician acceptance and seamless workflow integration, paving the way for a market entry strategy that leverages concentrated, high‑volume maternity centers. Singapore serves as the launchpad, where memoranda of understanding with NUHS and KKH cover roughly half of the nation’s births, allowing the company to collect robust real‑world data before scaling to the United States, where each unit’s $200‑plus price tag can offset $15,000‑$70,000 in avoided treatment costs per severe tear.

Beyond the device itself, Peripear highlights a broader shift in medtech toward clinician‑led innovation and gender‑balanced entrepreneurship. Winning the Female Founders pitch at SCALE and securing a £800 k pre‑seed round—backed by Zinc VC and others—signals growing investor confidence in solutions that marry clinical insight with clear economic upside. As health‑equity concerns rise, especially for Black and Asian women who face higher tear rates, technologies like Peripear not only promise better outcomes but also illustrate how diverse founder perspectives can unlock market opportunities previously overlooked.